Multiple System Atrophy: Clinical Trials

2 trials for Multiple System Atrophy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Active not recruiting 2

Follow Multiple System Atrophy: new trials by email Literature Review of Multiple System Atrophy trials Research Report on Multiple System Atrophy

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
Amlenetug, Placebo - Multiple System Atrophy
Phase 3Active not recruitingH. Lundbeck A/S4012024-12-032026-10-14
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Phase 3Active not recruitingTheravance Biopharma1022023-06-272025-09-05

Narrower conditions

Neurodegenerative Diseases (1)  ·  Shy-Drager Syndrome (1)

Broader conditions

Autonomic Nervous System Diseases (2)  ·  Basal Ganglia Diseases (2)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Movement Disorders (2)  ·  Nervous System Diseases (2)  ·  Primary Dysautonomias (2)  ·  Cardiovascular Diseases (1)  ·  Hypotension (1)  ·  Synucleinopathies (1)  ·  Vascular Diseases (1)

Interventions

ampreloxetine (1)

Sponsors

H. Lundbeck A/S (1)  ·  Theravance Biopharma (1)

Countries

Australia (2)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Argentina (1)  ·  Austria (1)  ·  Brazil (1)  ·  Denmark (1)  ·  Estonia (1)  ·  Hungary (1)  ·  Israel (1)